DRMA
Dermata Therapeutics, Inc.
Price Chart
Latest Quote
$1.17
-0.16 (-12.03%)
Current Price
| Previous Close | $1.33 |
| Open | $1.31 |
| Day High | $1.35 |
| Day Low | $1.17 |
| Volume | 122,992 |
Stock Information
| Shares Outstanding | 4.02M |
| Cash Equivalents | $6.95M |
| Net Income | $-7.10M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.71M |
| EPS (TTM) | $-4.05 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-2.24M |
| Income | $-7.10M |
| Book/sh | $1.59 |
| Cash/sh | $1.73 |
| Employees | 9 |
Financial Ratios
| Quick Ratio | 6.60 |
| Current Ratio | 7.09 |
Returns & Margins
| ROA | -52.66% |
| ROE | -103.58% |
Ownership
| Insider Ownership | 24.82% |
| Institutional Ownership | 7.37% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.30 |
| P/B | 0.73 |
Analyst Data
| Recommendation | none |
| Target Price | $4.00 |
Technical Indicators
| SMA20 | $1.25 |
| SMA50 | $1.26 |
| SMA200 | $2.44 |
| RSI | 40.58 |
| ATR | 0.0866 |
| Shares Float | 3.17M |
| Short Float | 3.06% |
| Short Ratio | 1.84 |
| Volatility | 0.69 |
| Rel Volume | 1.92 |
Performance History
| Week | -4.10% |
| Month | -0.85% |
| Quarter | -3.31% |
| 6 Months | -49.57% |
| YTD | -46.33% |
| Year | -83.47% |
| 3 Years | -99.56% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.17 | 123,000 |
| 2026-06-17 | $1.33 | 139,000 |
| 2026-06-16 | $1.19 | 41,000 |
| 2026-06-15 | $1.20 | 42,200 |
| 2026-06-12 | $1.18 | 40,500 |
| 2026-06-11 | $1.22 | 42,900 |
| 2026-06-10 | $1.19 | 56,200 |
| 2026-06-09 | $1.20 | 42,900 |
| 2026-06-08 | $1.21 | 32,700 |
| 2026-06-05 | $1.18 | 57,800 |
| 2026-06-04 | $1.25 | 69,500 |
| 2026-06-03 | $1.27 | 88,700 |
| 2026-06-02 | $1.36 | 89,500 |
| 2026-06-01 | $1.34 | 96,900 |
| 2026-05-29 | $1.30 | 56,000 |
| 2026-05-28 | $1.35 | 61,400 |
| 2026-05-27 | $1.30 | 53,400 |
| 2026-05-26 | $1.23 | 62,700 |
| 2026-05-22 | $1.26 | 41,500 |
| 2026-05-21 | $1.24 | 43,000 |
| 2026-05-20 | $1.25 | 43,700 |
| 2026-05-19 | $1.18 | 42,800 |
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on DRMA.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $7,773,598 | $12,513,242 | $8,041,906 | $9,674,486 |
| Net Non Operating Interest Income Expense | $215,041 | $225,781 | $247,216 | $63,573 |
| Operating Expense | $7,773,598 | $12,513,242 | $8,041,906 | $9,674,486 |
| General And Administrative Expense | - | $4,309,551 | $3,972,140 | $4,023,445 |
| Interest Expense | - | - | - | $-63,573 |
| Total Other Finance Cost | - | - | - | $-63,573 |
| Interest Expense Non Operating | - | - | - | $-63,573 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Net Interest Income | $215,041 | $225,781 | $247,216 | $63,573 |
| Interest Income | $215,041 | $225,781 | $247,216 | $63,573 |
| Normalized Income | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Net Income From Continuing And Discontinued Operation | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Total Operating Income As Reported | $-7,773,598 | $-12,513,242 | $-8,041,906 | $-9,674,486 |
| Net Income Common Stockholders | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Net Income | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Net Income Including Noncontrolling Interests | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Net Income Continuous Operations | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Pretax Income | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Interest Income Non Operating | $215,041 | $225,781 | $247,216 | $63,573 |
| Operating Income | $-7,773,598 | $-12,513,242 | $-8,041,906 | $-9,674,486 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-8.16 | $-80.32 | $-399.90 | $-2088.00 |
| Basic EPS | $-8.16 | $-80.32 | $-399.90 | $-2088.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-7,773,598 | $-12,513,242 | $-8,041,906 | $-9,674,486 |
| EBITDA (Bullshit earnings) | $-7,773,598 | $-12,513,242 | $-8,041,906 | $-9,674,486 |
| EBIT | $-7,773,598 | $-12,513,242 | $-8,041,906 | $-9,674,486 |
| Diluted Average Shares | $926,192 | $152,974 | $19,492 | $4,604 |
| Basic Average Shares | $926,192 | $152,974 | $19,492 | $4,604 |
| Diluted NI Availto Com Stockholders | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Research And Development | $2,929,983 | $8,203,691 | $4,069,766 | $5,651,041 |
| Selling General And Administration | $4,843,615 | $4,309,551 | $3,972,140 | $4,023,445 |
| Other Gand A | - | $4,309,551 | $3,972,140 | $4,023,445 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
| Reconciled Depreciation | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,223,380 | $1,561,094 | $6,355,018 | $6,021,854 |
| Total Assets | $7,863,826 | $3,533,888 | $7,978,634 | $6,944,488 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $7,863,826 | $3,533,888 | $7,978,634 | $6,944,488 |
| Prepaid Assets | $341,848 | $372,318 | $540,499 | $690,592 |
| Cash Cash Equivalents And Short Term Investments | $7,521,978 | $3,161,570 | $7,438,135 | $6,241,294 |
| Cash And Cash Equivalents | $7,521,978 | $3,161,570 | $7,438,135 | $6,241,294 |
| Other Current Assets | - | - | $14,498 | $11,604 |
| Receivables | - | - | $8,356 | $12,602 |
| Accrued Interest Receivable | - | - | $8,356 | $12,602 |
| Current Deferred Assets | - | - | - | $0 |
| Other Receivables | - | - | - | $12,602 |
| Cash Financial | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,640,446 | $1,972,794 | $1,623,616 | $922,634 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $1,640,446 | $1,972,794 | $1,623,616 | $922,634 |
| Payables And Accrued Expenses | $660,993 | $1,241,162 | $907,126 | $752,245 |
| Payables | $460,811 | $808,011 | $866,028 | $496,702 |
| Accounts Payable | $460,811 | $808,011 | $866,028 | $496,702 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $6,223,380 | $1,561,094 | $6,355,018 | $6,021,854 |
| Total Equity Gross Minority Interest | $6,223,380 | $1,561,094 | $6,355,018 | $6,021,854 |
| Stockholders Equity | $6,223,380 | $1,561,094 | $6,355,018 | $6,021,854 |
| Retained Earnings | $-73,233,896 | $-65,675,339 | $-53,387,878 | $-45,593,188 |
| Other | ||||
| Ordinary Shares Number | $2,660,110 | $251,776 | $26,205 | $5,134 |
| Share Issued | $2,660,110 | $251,776 | $26,205 | $5,134 |
| Tangible Book Value | $6,223,380 | $1,561,094 | $6,355,018 | $6,021,854 |
| Invested Capital | $6,223,380 | $1,561,094 | $6,355,018 | $6,021,854 |
| Working Capital | $6,223,380 | $1,561,094 | $6,355,018 | $6,021,854 |
| Total Capitalization | $6,223,380 | $1,561,094 | $6,355,018 | $6,021,854 |
| Additional Paid In Capital | $79,457,010 | $67,236,408 | $59,742,870 | $51,614,965 |
| Capital Stock | $266 | $25 | $26 | $77 |
| Common Stock | $266 | $25 | $26 | $77 |
| Pensionand Other Post Retirement Benefit Plans Current | $979,453 | $731,632 | $716,490 | $170,389 |
| Current Accrued Expenses | $200,182 | $433,151 | $41,098 | $255,543 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,757,559 | $-11,162,948 | $-6,408,931 | $-8,834,164 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,757,559 | $-11,162,948 | $-6,408,931 | $-8,834,164 |
| Cash Flow From Continuing Operating Activities | $-7,757,559 | $-11,162,948 | $-6,408,931 | $-8,834,164 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-367 | $-828 | $-40 | $0 |
| Issuance Of Capital Stock | $12,167,852 | $6,886,102 | $7,605,625 | $4,276,365 |
| Financing Cash Flow | $12,117,967 | $6,886,383 | $7,605,772 | $4,276,652 |
| Cash Flow From Continuing Financing Activities | $12,117,967 | $6,886,383 | $7,605,772 | $4,276,652 |
| Net Other Financing Charges | $-50,495 | - | - | - |
| Net Common Stock Issuance | $12,167,485 | $6,885,274 | $7,605,585 | $4,276,365 |
| Common Stock Issuance | $12,167,852 | $6,886,102 | $7,605,625 | $4,276,365 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $950 | $950 | $950 | $950 |
| End Cash Position | $7,521,978 | $3,161,570 | $7,438,135 | $6,241,294 |
| Beginning Cash Position | $3,161,570 | $7,438,135 | $6,241,294 | $10,798,806 |
| Changes In Cash | $4,360,408 | $-4,276,565 | $1,196,841 | $-4,557,512 |
| Proceeds From Stock Option Exercised | $977 | $1,109 | $187 | $287 |
| Common Stock Payments | $-367 | $-828 | $-40 | $0 |
| Change In Working Capital | $-342,734 | $466,864 | $863,677 | $-153,576 |
| Change In Payables And Accrued Expense | $-373,204 | $298,683 | $700,982 | $-275,516 |
| Change In Accrued Expense | $14,852 | $407,195 | $331,656 | $-256,973 |
| Change In Payable | $-388,056 | $-108,512 | $369,326 | $-18,543 |
| Change In Account Payable | $-388,056 | $-108,512 | $369,326 | $-18,543 |
| Change In Prepaid Assets | $30,470 | $168,181 | $162,695 | $121,940 |
| Stock Based Compensation | $143,732 | $657,649 | $522,082 | $930,325 |
| Net Income From Continuing Operations | $-7,558,557 | $-12,287,461 | $-7,794,690 | $-9,610,913 |
| Repayment Of Debt | - | - | - | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Preferred Stock Payments | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
| Change In Other Current Liabilities | - | - | - | - |
| Other Non Cash Items | - | - | - | - |
| Depreciation Amortization Depletion | - | - | - | - |
| Depreciation And Amortization | - | - | - | - |
| Depreciation | - | - | - | - |
Fetched: 2026-06-19